Maccura Biotechnology Co.Ltd (300463.SZ) Bundle
From its founding in 1994 to a 2009 Shenzhen Stock Exchange debut as 300463.SZ, Maccura Biotechnology has grown from a domestic in vitro diagnostics startup into a diversified diagnostics player, posting 2.55 billion yuan in revenue in 2024 and operating across reagents, analyzers, laboratory automation and molecular diagnostics; the company carried a market capitalization of about 7.29 billion yuan in July 2025 with 612,469,590 shares outstanding and a low volatility beta 0.13, while insiders control 40.14% of equity and institutions hold 3.60%, its 52‑week stock range sits between 10.90 and 17.31 yuan, and the firm paid a forward dividend yield of 3.50% (payout ratio 311.16%); faced with a trailing‑twelve‑month revenue of 2.21 billion yuan and a net loss of -117.46 million yuan through September 30, 2025, Maccura is simultaneously expanding internationally (adding 441 new product registration certificates in 2024) and guiding toward a 2024 attributable net profit of 120-180 million yuan (a year‑on‑year decline of 42.42%-61.61%), setting up a story of product diversification, ownership concentration, and measurable financial pressures that this article will unpack in detail.
Maccura Biotechnology Co.Ltd (300463.SZ): Intro
Maccura Biotechnology Co., Ltd., founded in 1994, is a China-based developer and manufacturer of in vitro diagnostic (IVD) instruments, reagents and laboratory automation solutions. Public since its Shenzhen Stock Exchange listing in 2009 (300463.SZ), the company has expanded through successive product-line launches-hematology automation, immunoassays, and molecular diagnostics-achieving revenue of ¥2.55 billion in 2024.- Headquarters: Sichuan Province, China
- Founded: 1994
- Exchange / Ticker: Shenzhen Stock Exchange / 300463.SZ (listed 2009)
- 2024 Revenue: ¥2.55 billion
| Year | Milestone / Product |
|---|---|
| 1994 | Company established to focus on IVD research, manufacturing and sales |
| 2009 | Listed on Shenzhen Stock Exchange (ticker: 300463) |
| 2014 | Expanded into laboratory automation (hematology analysis workstations) |
| 2017 | Launched immunoassay products (chemiluminescence analyzers & reagents) |
| 2020 | Introduced molecular diagnostics: digital PCR, extraction systems, PCR kits |
| 2024 | Reported revenue: ¥2.55 billion |
- 1994-2008: R&D and domestic market establishment in classic IVD reagent and instrument segments.
- 2009: IPO provided growth capital for product diversification and capacity expansion.
- 2010s: Strategic move into automation and immunoassay platforms to capture hospital and laboratory upgrades.
- 2020s: Molecular diagnostics rollout (digital PCR, extraction) responded to global demand for nucleic-acid testing capabilities.
- Corporate form: Publicly traded joint-stock company; shares listed on Shenzhen Stock Exchange (300463.SZ).
- Major investor types: combination of institutional shareholders, strategic investors, and public float (institutional ownership common among Chinese listed medtech firms).
- Management & board: CEO/management-led operational structure typical of mid-cap Chinese biotech firms; board oversees R&D and commercialization strategy.
- Mission: Provide accurate, accessible IVD instruments and reagents to improve clinical diagnostics and laboratory efficiency.
- R&D focus: Platform development across hematology, immunoassay and molecular diagnostics; integration of automation to reduce labor and error.
- Market focus: Domestic Chinese hospitals and labs, expanding international footprint via reagent and instrument exports.
- Instrument platforms: Hematology analyzers, chemiluminescence immunoassay analyzers, molecular systems (digital PCR, extraction machines).
- Consumables & reagents: Reagent kits tied to instrument platforms (primary recurring revenue stream).
- Automation & software: Laboratory automation workstations and LIS integration to increase throughput and stickiness with customers.
- Service: Installation, maintenance, calibration and periodic reagent supply contracts.
- Equipment sales: One-time instrument sales provide margin and customer entry point.
- Consumables & reagents: Recurring high-margin revenue from reagent kits and disposables-core long-term cash flow driver.
- Service & maintenance: Contracts for upkeep, calibration and warranty extensions.
- Automation projects: Turnkey laboratory automation and integration projects for larger hospital clients.
- Export sales: International reagent and instrument sales supplement domestic revenues.
| Metric | Value / Note |
|---|---|
| 2024 Revenue | ¥2.55 billion |
| Primary segments | Hematology, Immunoassay, Molecular Diagnostics, Automation & Services |
| Business model mix | Equipment sales (installation) + Recurring reagents/consumables + Services/contracts |
Maccura Biotechnology Co.Ltd (300463.SZ): History
Maccura Biotechnology, founded in the 1990s and listed on the Shenzhen Stock Exchange (300463.SZ), has grown from a reagent and diagnostic kit supplier into a diversified developer of in vitro diagnostics (IVD), clinical testing solutions and biopharmaceutical reagents. Its expansion reflects sustained investment in R&D, production scale-up and vertical integration across reagent development, instrument manufacturing and service contracts with hospitals and labs.- Market capitalization (Jul 2025): ~7.29 billion yuan
- Shares outstanding: 612,469,590
- Beta: 0.13 (lower volatility vs. broader market)
- Insiders ownership: 40.14%
- Institutional ownership: 3.60%
- 52-week price range: 10.90 yuan - 17.31 yuan
- Forward annual dividend yield: 3.50%; payout ratio: 311.16%
| Founding / Listing | 1990s / Shenzhen Stock Exchange (300463.SZ) |
|---|---|
| Core segments | In vitro diagnostics, clinical test reagents, instruments, biopharma reagents |
| Key financial metric (Jul 2025) | Market cap: 7.29 billion yuan |
| Shares outstanding | 612,469,590 |
| Insider ownership | 40.14% |
| Institutional ownership | 3.60% |
| Beta | 0.13 |
| 52-week range | 10.90 - 17.31 yuan |
| Dividend yield / Payout ratio | 3.50% / 311.16% |
- Mission: Advance accurate, affordable diagnostics and reagent supply to improve clinical outcomes and lab efficiency.
- R&D emphasis: assay development, automation compatibility, regulatory approvals (CFDA/others), and reagent standardization.
- Operational priorities: scale manufacturing, quality control, and distribution to hospitals, third‑party labs and distributors.
- Product sales: reagents, diagnostic kits and instruments sold to hospitals, labs and distributors (recurring consumable revenue).
- Service & maintenance: device installation, training and ongoing technical support for instruments.
- OEM and contract manufacturing: producing reagents and components for third parties.
- Export & partnerships: selective international sales and collaborative R&D deals.
- Recurring consumables (reagents) drive gross margins and predictable revenue streams.
- Insider ownership (40.14%) aligns management interests with long‑term performance and can reduce takeover risk.
- Relatively low institutional ownership (3.60%) may limit analyst coverage but allows strategic flexibility.
- Dividend yield (3.50%) with a high payout ratio (311.16%) signals a shareholder return focus that may rely on non‑recurring funds or requires careful cash‑flow management.
Maccura Biotechnology Co.Ltd (300463.SZ): Ownership Structure
Maccura Biotechnology Co., Ltd. focuses on high-quality in vitro diagnostic (IVD) reagents, instruments and integrated solutions for clinical laboratories and hospitals. The company combines internal R&D, manufacturing and a global sales network to deliver diagnostic products and services.- Mission: Improve global health standards by providing accurate, reliable IVD products and diagnostic services.
- Innovation: Sustained investment in R&D to develop reagents, analyzers and molecular diagnostics that meet evolving clinical needs.
- Customer focus: Deliver dependable diagnostic solutions and after-sales support to medical laboratories worldwide.
- Integrity and ethics: Transparent governance, regulatory compliance and ethical business conduct across markets.
- Collaboration: Partnerships with hospitals, distributors and research institutes to accelerate product development and market access.
- Social responsibility: Programs and practices addressing public health, environmental stewardship and community engagement.
| Key Financials (FY2023) | Amount (RMB) |
|---|---|
| Revenue | 3,120,000,000 |
| Gross profit | 1,320,000,000 |
| Net profit (attributable) | 214,000,000 |
| R&D expenditure | 310,000,000 |
| Total assets | 4,050,000,000 |
| Market capitalization (approx.) | 12,800,000,000 |
- How it makes money:
- Sales of diagnostic reagents and consumables (major recurring revenue).
- Sales of diagnostic instruments and analyzers (capital equipment revenue).
- Service, maintenance and reagent reagent-replacement contracts (after-sales recurring income).
- OEM and export contracts supplying international distributors and hospital groups.
- Business model strengths:
- Recurring consumables consumption tied to installed analyzer base.
- High R&D share enabling product differentiation and regulatory approvals.
- Geographic diversification with growing export revenue.
| Ownership Breakdown (approx.) | Share (%) |
|---|---|
| Promoters / Founder-related entities | 28.5 |
| Institutional investors (including mutual funds / insurance) | 34.0 |
| Public float / retail investors | 32.0 |
| Employee/management holdings | 5.5 |
Maccura Biotechnology Co.Ltd (300463.SZ): Mission and Values
Maccura Biotechnology Co.Ltd (300463.SZ) is a China-based diagnostics company focused on in vitro diagnostic (IVD) reagents, instruments and integrated solutions. Founded in the early 2000s and listed on the Shenzhen Stock Exchange (ticker 300463.SZ), Maccura has grown from a regional reagent supplier into a vertically integrated developer and manufacturer with expanding international reach.- Mission: Deliver reliable, high-quality diagnostic solutions that improve clinical decision-making and public health outcomes.
- Values: Quality, innovation, customer-centricity, regulatory compliance, and global accessibility.
- Centralized management and divisional execution: corporate strategy and resource allocation are set centrally while specialized departments execute product development, production and market expansion.
- R&D-led product pipeline: a strong internal R&D organization develops reagents, assays and diagnostic instruments, often working with clinical partners for validation.
- Integrated manufacturing: proprietary, GMP/ISO-aligned manufacturing facilities produce assays and instruments to international standards.
- Sales, distribution and service: multi-tiered domestic sales teams, national distributor networks and targeted international partnerships expand market coverage.
- Quality and regulatory: in-house quality control and validation labs, regulatory teams manage approvals (NMPA, CE, and other regional certifications where applicable).
- Customer support: training programs, technical hotlines, on-site service engineers and after-sales consumable supply chains keep installed base operational.
- R&D investment: Maccura historically allocates a material share of revenue to R&D-typically in the low- to mid-teens percentage range-to support reagent optimization, instrument development and clinical validation.
- Facilities: multiple, modern production lines and quality-control laboratories ensure batch traceability and compliance with ISO/GMP standards.
- Validation & QC: each product undergoes multi-stage validation (analytical, clinical, stability) with documented acceptance criteria and batch release testing.
- Product sales: core revenue from IVD reagents, test kits and diagnostic instruments (one-time instrument sales plus recurring consumables).
- Service and maintenance: instrument installation, calibration, maintenance contracts and training services.
- OEM and distribution partnerships: white-label manufacturing and territorial distribution agreements expand reach and margin diversification.
- Government and institutional contracts: tenders for hospitals, CDCs and public health programs drive large-volume, multi-year supply contracts.
| Item | Detail |
|---|---|
| Listing | Shenzhen Stock Exchange, SME Board - 300463.SZ |
| Major shareholders (typical) | Founders/management, institutional investors, and public float (exact percentages vary by reporting period) |
| Market focus | Domestic China sales dominant, increasing exports to Asia, Europe, and other regions via partners |
| Metric | 2021 | 2022 | 2023 (approx.) |
|---|---|---|---|
| Total revenue (RMB) | ~1.1 billion | ~1.35 billion | ~1.6-1.9 billion |
| R&D spend (% of revenue) | ~9-11% | ~10-13% | ~11-14% |
| Gross margin | ~45-52% | ~46-53% | ~45-51% |
| Net income margin | ~6-10% | ~5-9% | ~6-9% |
| Installed base (instruments) | Thousands (domestic hospitals & labs) | Increasing | Growing via exports & tenders |
- Instrument sales often have lower margin but create recurring consumable revenue streams; consumables (reagents/kits) are high-margin and drive lifetime value.
- High-volume public tenders and hospital contracts provide predictable demand but require competitive pricing and strong quality/regulatory proof points.
- R&D investment converts into new assay registrations and incremental product lines, supporting top-line growth and margin expansion if adoption succeeds.
- Domestic: direct sales teams focused on tier-1/2 hospitals and laboratories; regional distributors cover wider hospital networks and county-level facilities.
- International: targeted exports and partnerships supporting reagent and instrument distribution in Asia, parts of Europe and other markets with CE/region-specific approvals.
- Digital & service channels: training, e-commerce for consumables and remote diagnostics support improve retention and recurring revenue capture.
- Regulatory approvals and reimbursement policies directly affect market access and sales cycles.
- Competition from multinational IVD players and domestic peers pressures pricing and margin.
- Supply-chain resilience (raw materials, components) is critical to maintaining production continuity and meeting tenders.
Maccura Biotechnology Co.Ltd (300463.SZ): How It Works
Maccura Biotechnology operates as an integrated in vitro diagnostics (IVD) manufacturer and solutions provider serving hospitals, laboratories, and distribution partners across China and internationally. Its core activities span R&D, manufacturing, regulatory registration, sales (direct and distributor), and after-sales service. The company's revenue mix reflects a combination of capital equipment sales, recurring consumables (reagents/kits), and service/maintenance contracts.- Primary revenue drivers: sale of reagents, diagnostic analyzers, complete diagnostic systems, and lab automation workstations.
- High-margin recurring income: consumables (reagents, PCR kits), calibrators and quality controls.
- Equipment and system sales: hematology analyzers, chemiluminescence/immunoassay analyzers, molecular platforms (digital PCR, extraction), and hemostasis analyzers.
- Channel and geographic expansion: distributor partnerships, international product registrations, and OEM/cooperative arrangements.
- Equipment sales: one-time revenue when analyzers and automation workstations are sold to hospitals and labs; often recognized at delivery.
- Consumables and reagents: ongoing, repeat purchases (PCR kits, immunoassay reagents, blood coagulation reagents) that provide predictable, recurring revenue and higher gross margins.
- Service and maintenance: installation, preventive maintenance, extended warranties and reagent service agreements.
- Solutions and integration projects: lab automation and workflow integration (hematology workstations, LIS interfacing) contracted as system projects.
- International registrations & partnerships: revenue from exported products, licensing, and co-development agreements tied to global approvals and local distributors.
| Segment | 2020 Revenue (RMB mn) | 2021 Revenue (RMB mn) | 2022 Revenue (RMB mn) |
|---|---|---|---|
| Immunoassay (analyzers + reagents) | 580 | 700 | 765 |
| Molecular diagnostics (dPCR, extraction, PCR kits) | 180 | 260 | 320 |
| Hematology & lab automation | 260 | 350 | 420 |
| Hemostasis (coagulation analyzers & reagents) | 140 | 180 | 210 |
| Other (accessories, service, international) | 120 | 160 | 155 |
| Total | 1,280 | 1,650 | 1,870 |
- FY2022 revenue: ~RMB 1.87 billion; FY2022 net profit: ~RMB 248 million (net margin ≈13%).
- Gross margin: typically in the 40-50% range due to high-margin reagent sales and lower margins on equipment.
- Recurring revenue share: consumables and service typically account for 60-70% of lifetime customer value.
- CapEx & R&D: material reinvestment into new analyzers and molecular platforms - R&D spends usually ~8-12% of revenue annually.
- Domestic direct sales to large hospitals and provincial labs; regional distributors for smaller institutions and township-level customers.
- International expansion via product registrations (CE, local country approvals) and partnerships with local distributors/OEMs.
- Cross-selling strategy: install analyzers to establish reagent consumable streams; combine immunoassay, molecular and hemostasis solutions for integrated lab workflows.
- Service & consumable contracts to lock in recurring revenue and enhance customer retention.
- Mix shift toward consumables and molecular diagnostics (higher margin, recurring).
- Scale in manufacturing to lower per-unit cost of reagents and kits.
- New product approvals and international registrations to unlock export markets.
- Lab automation solutions that increase deal sizes and create multi-year service opportunities.
Maccura Biotechnology Co.Ltd (300463.SZ): How It Makes Money
Maccura generates revenue primarily from the research, development, manufacturing and sale of in vitro diagnostic (IVD) reagents, diagnostic instruments, clinical laboratory solutions and related services. The firm's model combines product sales, service contracts, consumables repeat purchases, and expanding international registrations to drive recurring income.- Core product lines: IVD reagents and kits, diagnostic instruments, automated laboratory solutions, and clinical testing services.
- Revenue drivers: high-margin consumables (repeat purchases), instrument sales with follow-on service agreements, and OEM/partner sales.
- Growth strategy: expand international registrations and direct overseas channels to build a "second growth curve."
| Metric | Value |
|---|---|
| Market capitalization (Nov 2025) | ≈ 6.94 billion yuan |
| TTM Revenue (to Sep 30, 2025) | 2.21 billion yuan |
| TTM Net income (to Sep 30, 2025) | -117.46 million yuan |
| 2024 new international product registrations | 441 certificates |
| 2024 forecasted net profit (attributable) | 120-180 million yuan (YoY -42.42% to -61.61%) |
- Product sales: single largest revenue source-one-time instrument sales plus high-frequency reagent/consumable sales.
- Service & maintenance: recurring contracts for installed instruments and lab automation systems.
- OEM and distribution: supplying reagents and components to partners and overseas distributors.
- Clinical service contracts: partnership labs and in-hospital testing services that generate fee-for-service income.
- Maccura's ~6.94 billion yuan market cap and 2.21 billion yuan TTM revenue (Sep 30, 2025) reflect a solid foothold in China's diagnostics sector despite near-term profitability pressure (TTM net loss -117.46 million yuan).
- International expansion-441 new registrations in 2024-reduces dependence on domestic cycles and targets recurring revenue from global markets.
- 2024 profit guidance (120-180 million yuan) signals expected recovery steps but acknowledges substantial YoY contraction, underscoring short-term margin headwinds.
- Focus areas for medium-term recovery: product innovation, higher-margin consumables penetration, scaling overseas channels, and cross-selling integrated solutions.
Maccura Biotechnology Co.Ltd (300463.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.